Newron Pharmaceuticals SpA (FRA:NP5) Institutional Ownership: 5.79% (As of Jul. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:NP5 Newron Pharmaceuticals SpA FRA:NP5
61 GF Score
Price €12.10
GF Value €13.65
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Newron Pharmaceuticals SpA Institutional Ownership?

Newron Pharmaceuticals SpA FRA:NP5 -1.63% 61 Institutional Ownership is 5.79% as of Jul. 20, 2026. GuruFocus rates FRA:NP5 with a GF Score™ of 61/100 and a GF Value™ of €13.65 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Newron Pharmaceuticals SpA's institutional ownership is 5.79%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Newron Pharmaceuticals SpA's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Newron Pharmaceuticals SpA's Float Percentage Of Total Shares Outstanding is 0.00%.

Newron Pharmaceuticals SpA Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Newron Pharmaceuticals SpA's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Newron Pharmaceuticals SpA Institutional Ownership Chart

Newron Pharmaceuticals SpA Historical Data

The historical data trend for Newron Pharmaceuticals SpA can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 5.11 5.50 6.53 7.01 7.91 8.11 7.84 8.16 6.82 5.79
FRA:NP5
61GF Score
Newron Pharmaceuticals SpA FRA:NP5
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Newron Pharmaceuticals SpA Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 5.79% mean?
Newron Pharmaceuticals SpA (FRA:NP5) has a Institutional Ownership of 5.79% as of Jul. 20, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Newron Pharmaceuticals SpA and its competitors.
Is Newron Pharmaceuticals SpA's Institutional Ownership too high?
Newron Pharmaceuticals SpA's current Institutional Ownership is 5.79%. Overall, Newron Pharmaceuticals SpA has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Newron Pharmaceuticals SpA's Institutional Ownership compare to VRTX and REGN?
Newron Pharmaceuticals SpA's Institutional Ownership of 5.79% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Newron Pharmaceuticals SpA and its competitors. Newron Pharmaceuticals SpA's current Institutional Ownership is 5.79%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Newron Pharmaceuticals SpA stock overvalued right now?
Based on GuruFocus' analysis, Newron Pharmaceuticals SpA (FRA:NP5) is currently considered Modestly Undervalued. The stock's GF Value™ is €13.65, compared to a current price of €12.10 — trading 11.4% below its estimated fair value. The current Institutional Ownership is 5.79%. Newron Pharmaceuticals SpA's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Newron Pharmaceuticals SpA (FRA:NP5), the current Institutional Ownership is 5.79% as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Newron Pharmaceuticals SpA (FRA:NP5) Overvalued in 2026?

Based on GuruFocus' analysis, Newron Pharmaceuticals SpA stock appears to be undervalued. The current stock price of €12.10 is trading 11.4% below its estimated GF Value™ of €13.65. GuruFocus considers Newron Pharmaceuticals SpA to be Modestly Undervalued.

Key valuation signals for FRA:NP5:

  • Institutional Ownership: 5.79%
  • GF Value™: €13.65 vs. price of €12.10 (11.4% below fair value)
  • GF Score™: 61/100 with 5 warning signs

No single metric tells the full story. See the FRA:NP5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Newron Pharmaceuticals SpA Business Description

Address Via Antonio Meucci 3, Bresso, Milan, ITA, 20091
Newron Pharmaceuticals SpA is a Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson's disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Geographically the research and development activities are performed in Italy and the United States.
61GF Score

Get the complete analysis for FRA:NP5

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€12.10
Price
€13.65
GF Value